Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson innovative Medicine goodwill ($M) ($M)
Form 10-Q / 10-K Goodwill & Intangible Assets Note
Latest, Q3 2026
14,748
Period ended Sep 30, 2026
Change on a year earlier
+3.4%
14,268 in Q3 2025
History
38 quarters
Since Q4 2015
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Innovative Medicine goodwill ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 14,748 | +3.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 14,755 | +3.0% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 14,812 | +35.8% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 14,967 | +40.0% | Form 10-Q (filed 2026-10-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 14,268 | +28.4% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2025 | Jun 29, 2025 | 14,326 | +33.0% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2025 | Mar 30, 2025 | 10,907 | +3.4% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2024 | Dec 29, 2024 | 10,692 | +2.7% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 11,112 | +9.5% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2024 | Jun 30, 2024 | 10,768 | +4.3% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2024 | Mar 31, 2024 | 10,552 | +2.4% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 10,407 | +2.2% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 10,149 | +5.1% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2023 | Jul 2, 2023 | 10,321 | +2.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2023 | Apr 2, 2023 | 10,308 | -1.0% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Jan 1, 2023 | 10,184 | -3.7% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 9,660 | -9.9% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 10,035 | -7.1% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2022 | Apr 3, 2022 | 10,410 | -3.1% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Jan 2, 2022 | 10,580 | -3.9% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 10,726 | +13.5% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2021 | Jul 4, 2021 | 10,805 | +17.3% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 10,747 | +18.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Jan 3, 2021 | 11,009 | +20.1% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 9,450 | +5.3% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2020 | Jun 28, 2020 | 9,215 | +1.2% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2020 | Mar 29, 2020 | 9,074 | +1.0% | Form 10-Q (filed 2020-04-29) ↗ |
| Q4 2019 | Dec 29, 2019 | 9,169 | +1.2% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 8,977 | -1.5% | Form 10-Q (filed 2019-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 9,104 | +0.7% | Form 10-Q (filed 2019-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 8,988 | -2.9% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 9,063 | -0.5% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 9,112 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 9,042 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 9,256 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 9,109 | +220.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2016 | Jan 1, 2017 | 2,840 | -1.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2015 | Jan 3, 2016 | 2,889 | – | Form 10-K (filed 2018-02-21) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson Innovative Medicine goodwill ($M) ($M), quarterly Q4 2015–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_goodwill_im
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.